A Dimitrios Colevas
Overview
Explore the profile of A Dimitrios Colevas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
10168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colevas A, Cmelak A, Pfister D, Spencer S, Adkins D, Birkeland A, et al.
J Natl Compr Canc Netw
. 2025 Feb;
23(2):2-11.
PMID: 39938471
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary...
2.
Colevas A, Talebi Z, Winters E, Even C, Lee V, Gillison M, et al.
Clin Cancer Res
. 2025 Jan;
31(5):815-823.
PMID: 39831818
Purpose: A first-in-human phase I study was conducted in patients with nasopharyngeal carcinoma to assess the safety and tolerability of VK-2019, a small-molecule selective inhibitor of Epstein-Barr virus (EBV) nuclear...
3.
Flanagan K, Earls J, Hiken J, Wellinghoff R, Ponder M, McLeod H, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39489541
Background: Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for...
4.
Pan J, Mai H, Ng W, Hu C, Li J, Chen X, et al.
JAMA Oncol
. 2024 Oct;
PMID: 39388190
Importance: Accurate staging is a fundamental step in treating patients with nasopharyngeal carcinoma (NPC) worldwide; this is crucial not only for prognostication, but also for guiding treatment decisions. The American...
5.
Gensheimer M, Teuteberg W, Patel M, Gupta D, Noroozi M, Ling X, et al.
J Natl Cancer Inst
. 2024 Sep;
117(2):296-302.
PMID: 39348179
Background: Advance care planning and serious illness conversations can help clinicians understand patients' values and preferences. Data are limited on how to increase the number of these conversations and what...
6.
Sun L, Cohen R, Colevas A
Oral Oncol
. 2024 Aug;
158:106997.
PMID: 39159526
Objectives: Pembrolizumab +/- chemotherapy is standard therapy for r/m HNSCC. Despite regulatory approval of platinum/5FU/pembrolizumab, a taxane is often substituted for 5FU for convenience and tolerability. We aimed to characterize...
7.
Hung G, Vohra S, Kim G, Jamal A, Srinivasan M, Huang R, et al.
Head Neck
. 2024 Jul;
46(12):3046-3055.
PMID: 39022914
Background: Nasopharyngeal carcinoma (NPC) mortality varies based on multiple risk factors. While NPC mortality is higher in Asia, little is known about Asian subgroups in the United States (US). Methods:...
8.
Davis M, Anders N, Colevas A, Messick T, Rudek M
Biomed Chromatogr
. 2023 Nov;
38(2):e5775.
PMID: 37942577
EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells....
9.
Lee N, Harris J, Kim J, Garden A, Mechalakos J, Pfister D, et al.
JAMA Netw Open
. 2023 Jun;
6(6):e2316094.
PMID: 37266942
Importance: The long-term outcomes associated with adding bevacizumab, a vascular endothelial growth factor inhibitor, to standard chemoradiation have continued to be favorable for a group of patients with locoregionally advanced...
10.
Jun M, Pinto H, Le Q, Quon A, Hara W, Coty J, et al.
PLoS One
. 2023 Feb;
18(2):e0276651.
PMID: 36730145
Objectives: A phase II = design is used to evaluate the efficacy and feasibility of full dose docetaxel, platinum, and 5-fluorouracil (TPF) in a sequential chemoradiation treatment locally advanced (LA)...